Skip to main
LLY

Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly (LLY) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 5%
Sell 5%
Strong Sell 0%

Bulls say

Eli Lilly is confident in the success of their Phase 2 combo trial for eloralintide and tirzepatide in overweight and obese patients with T2D, projected to have risk-adjusted sales of $13.6B in 2032, driven by pent-up demand for a new weight-loss monotherapy and promising combination potential. The combination of eloralintide and tirzepatide in a single injection could also offer a better efficacy and tolerability ratio compared to tirzepatide monotherapy. Additionally, Eli Lilly's focus on neuroscience, cardiometabolic, cancer, and immunology with key products such as Verzenio, Jardiance, Taltz, and Olumiant, positions the company for continued growth despite competition and potential regulatory threats in the PBM market.

Bears say

Eli Lilly is a well-established drug firm with a diverse portfolio of products targeting major medical areas such as cancer, cardiometabolic diseases, and immunology. However, with recent concerns over the potential of adverse effects in clinical trials and the company's reliance on a few key products, there is a negative outlook for the stock. Additionally, the company's earnings and financials may be impacted by ongoing challenges in the retail and pharmacy reimbursement sectors, potentially leading to slower revenue growth and profitability.

Eli Lilly (LLY) has been analyzed by 20 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 5% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eli Lilly (LLY) Forecast

Analysts have given Eli Lilly (LLY) a Buy based on their latest research and market trends.

According to 20 analysts, Eli Lilly (LLY) has a Buy consensus rating as of Jul 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,274.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,274.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eli Lilly (LLY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.